Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health Cuts Q2 Loss in Half as Product Revenue Surges; Shares Jump 15 Percent

NEW YORK (GenomeWeb News) – Genomic Health said today net loss fell by nearly half in the second quarter as product revenues quintupled.
 
The results caused shares in the company to trade up almost 15 percent, or $1.61, at $12.47 in mid-afternoon today.
 
Receipts for the three months ended June 30 increased to $8.4 million from $1.2 million year over year, Genomic Health said. Oncotype DX product sales to Medicare and privately insured patients accounted for $7.8 million in revenue.
 
R&D costs increased 13 percent to $2.8 million from $2.4 million in the comparable quarter a year ago.
 
Genomic Health narrowed its net loss 39 percent in the quarter to $4.9 million from $8 million during the comparable period last year.
 
The company said it had around $21 million in cash and cash equivalents and $33.7 million in short-term investments as of June 30.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.